Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 11/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037655 | 0.90 | GRIN1 (0.53) | GRIN1GRIN2BCCR3KDM4ESMN1; SMN2 | |
| SCHEMBL6996569 | 0.79 | GRIN2B (0.52) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6996260 | 0.77 | GRIN1 (0.57) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL7401860 | 0.72 | DRD2 (0.66) | GRIN1 | |
| SCHEMBL7405352 | 0.71 | SLC6A2 (0.67) | GRIN1 | |
| SCHEMBL8543235 | 0.71 | GRIN2B (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL7406473 | 0.69 | GRIN1 (0.77) | GRIN1 | |
| SCHEMBL12619204 | 0.69 | GRIN1 (1.00) | GRIN1GRIN2B | |
| SCHEMBL6992524 | 0.69 | GRIN1 (0.57) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL8547576 | 0.69 | GRIN2B (0.67) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | GRIN1 1/4885GRIN2B 5/4885GRIN2D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.